Lapatinib Versus Placebo Added to Paclitaxel in First-Line Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Ethical Lessons Not Learned From Africa.

Lapatinib Versus Placebo Added to Paclitaxel in First-Line Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Ethical Lessons Not Learned From Africa. J Clin Oncol. 2013 Oct 14; Authors: Ades F PMID: 24127451 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24127451?dopt=Abstract

Source: Clinical Breast Cancer - October 14, 2013 Category: Cancer & Oncology Authors: Ades F Tags: J Clin Oncol Source Type: research